The potential negative impact of proton pump inhibitors on the immunopharmacologic effects of chloroquine and hydroxychloroquine

1 Wakelin SH  . Handbook of systemic drug treatment in dermatology. 1st ed. London: Manson Publishing Ltd; 2002. p. 75–80.

2 Callen PC  Camisa C  . Antimalarial agents, chapter 13. In: SE Wolverton  , (ed), Comprehensive dermatologic drug therapy, 2nd ed. China: Saunders Elsevier; 2007. p. 259–273.

3 Janeway CA  Travers P  Walport M  Shlomchik MJ  . Immunobiology. 6th ed. New York: Garland Science Publishing; 2005. p. 177.

4 Fox RI  Kang HI  . Mechanism of action of antimalarial drugs: inhibition of antigen processing and presentation. Lupus 1993; 2(Suppl. 1): S9–S12.

5 Jain KS  Shah AK  Bariwal J  . Recent advances in proton pump inhibitors and management of acid-peptic disorders. Bioorg Med Chem 2007; 15: 1181–1205.

6 Skinner-Adams T  Davis TME  . Synergistic in vitro antimalarial activity of omeprazole and quinine. Antimicrob Agents Chemother 1999; 43: 1304–1306.

7 Kochar DK  Saini G  Kochar SK  . A double blind, randomised placebo controlled trial of rifampicin with omeprazole in the treatment of human cutaneous leishmaniasis. J Vect Borne Dis 2006; 43: 161–167.

8 Chandra S  Adhikary G  Sikdar R  Sen PC  . The in vivo inhibition of transport enzyme activities by chloroquine in different organs of the rat is reversible. Mol Cell Biochem 1992; 118: 15–21.